|
WO1995003009A1
(en)
|
1993-07-22 |
1995-02-02 |
Oculex Pharmaceuticals, Inc. |
Method of treatment of macular degeneration
|
|
WO1995003807A1
(en)
|
1993-07-27 |
1995-02-09 |
The University Of Sydney |
Treatment of age-related macular degeneration
|
|
US5801195A
(en)
*
|
1994-12-30 |
1998-09-01 |
Celgene Corporation |
Immunotherapeutic aryl amides
|
|
IT1274549B
(it)
|
1995-05-23 |
1997-07-17 |
Indena Spa |
Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
|
|
US5800819A
(en)
|
1996-01-25 |
1998-09-01 |
National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology |
Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
|
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
US5635517B1
(en)
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
|
NZ333903A
(en)
|
1996-07-24 |
2000-02-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1oxoisoindolines and method of reducing TNF-alpha levels in a mammal
|
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
|
HN1998000115A
(es)
*
|
1997-08-21 |
1999-06-02 |
Warner Lambert Co |
Formas de dosificación farmacéuticas sólidas
|
|
US6015803A
(en)
|
1998-05-04 |
2000-01-18 |
Wirostko; Emil |
Antibiotic treatment of age-related macular degeneration
|
|
US6225348B1
(en)
|
1998-08-20 |
2001-05-01 |
Alfred W. Paulsen |
Method of treating macular degeneration with a prostaglandin derivative
|
|
US6001368A
(en)
|
1998-09-03 |
1999-12-14 |
Protein Technologies International, Inc. |
Method for inhibiting or reducing the risk of macular degeneration
|
|
US6667316B1
(en)
*
|
1999-11-12 |
2003-12-23 |
Celgene Corporation |
Pharmaceutically active isoindoline derivatives
|
|
US7182953B2
(en)
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
|
AU2002343220A1
(en)
|
2001-11-09 |
2003-05-19 |
Matsushita Electric Industrial Co., Ltd. |
Moving picture coding method and apparatus
|
|
US7323479B2
(en)
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
|
US20100129363A1
(en)
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
US20050203142A1
(en)
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
|
US20040091455A1
(en)
|
2002-10-31 |
2004-05-13 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
|
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
|
US20050100529A1
(en)
|
2003-11-06 |
2005-05-12 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
|
|
CA2547570A1
(en)
|
2003-12-02 |
2005-06-23 |
Celgene Corporation |
4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for induction of fetal hemoglobin in individuals having anemia
|
|
US20050143344A1
(en)
|
2003-12-30 |
2005-06-30 |
Zeldis Jerome B. |
Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
|
|
WO2005091991A2
(en)
|
2004-03-22 |
2005-10-06 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
|
|
US20050222209A1
(en)
|
2004-04-01 |
2005-10-06 |
Zeldis Jerome B |
Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
|
|
JP2007533761A
(ja)
|
2004-04-23 |
2007-11-22 |
セルジーン・コーポレーション |
肺高血圧症を治療し管理するための、免疫調節性化合物の使用方法及び免疫調節性化合物を含む組成物
|
|
US9504658B2
(en)
*
|
2004-11-09 |
2016-11-29 |
Board Of Regents, The University Of Texas System |
Stabilized HME composition with small drug particles
|
|
AU2005304420A1
(en)
|
2004-11-12 |
2006-05-18 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
|
|
AU2005309733A1
(en)
|
2004-11-23 |
2006-06-01 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
|
|
ATE499112T1
(de)
|
2005-09-01 |
2011-03-15 |
Celgene Corp |
Immunologische verwendungen von immunmodulatorischen verbindungen für einen impfstoff und therapie gegen infektionskrankheiten
|
|
JP2010526848A
(ja)
*
|
2007-05-11 |
2010-08-05 |
エフ．ホフマン−ラ ロシュ アーゲー |
難溶性薬物用の医薬組成物
|
|
US20110053942A1
(en)
*
|
2008-02-13 |
2011-03-03 |
Dainippon Sumitomo Pharma Co., Ltd. |
Orally disintegrating tablets
|
|
WO2009120296A1
(en)
*
|
2008-03-24 |
2009-10-01 |
Celgene Corporation |
Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
|
|
US9192578B2
(en)
*
|
2008-08-20 |
2015-11-24 |
Board Of Regents, The University Of Texas System |
Hot-melt extrusion of modified release multi-particulates
|
|
JP5513508B2
(ja)
|
2008-09-10 |
2014-06-04 |
セルジーン コーポレイション |
アミノスルホン化合物を調製するためのプロセス
|
|
PE20120580A1
(es)
|
2009-02-10 |
2012-05-23 |
Celgene Corp |
Metodos para utilizar y composiciones que comprenden moduladores pde4 para tratamiento, prevencion y control de tuberculosis
|
|
WO2011059931A2
(en)
|
2009-11-10 |
2011-05-19 |
Celgene Corporation |
Nanosuspension of a poorly soluble drug via microfluidization process
|
|
BR112012012999A2
(pt)
*
|
2009-11-30 |
2019-04-02 |
Aptalis Pharmatech Inc |
Composição farmacêutica, e composição de tablete de desintegração oral (odt) outablete de dispersão rápida (rdt)
|
|
CN103391770A
(zh)
*
|
2011-01-10 |
2013-11-13 |
细胞基因公司 |
环丙烷羧酸{2-[(1s)-1-(3-乙氧基-4-甲氧基-苯基)-2-甲烷磺酰基-乙基]-3-氧代-2,3-二氢-1h-异吲哚-4-基}-酰胺的口服剂型
|
|
RU2017121896A
(ru)
|
2011-09-14 |
2019-01-29 |
Селджин Корпорейшн |
Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты
|
|
WO2013101810A1
(en)
|
2011-12-27 |
2013-07-04 |
Celgene Corporation |
Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
|